Clinical Trials Directory

Trials / Completed

CompletedNCT02200237

A Clinical Study for Inactivated Vaccine Against EV71

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
366 (actual)
Sponsor
Medigen Vaccine Biologics Corp. · Industry
Sex
All
Age
2 Months – 12 Years
Healthy volunteers
Accepted

Summary

This study aims to evaluate the safety, reactogenicity and immunogenicity of EV71 vaccine in health children and infants aged from 2 months to \<12yrs.

Conditions

Interventions

TypeNameDescription
BIOLOGICALEV71 with adjuvant aluminium phosphateTwo arms, EV71 with aluminium phosphate
BIOLOGICALPlaceboPhosphate Buffer Saline with adjuvant aluminium phosphate

Timeline

Start date
2014-09-01
Primary completion
2017-05-01
Completion
2017-08-01
First posted
2014-07-25
Last updated
2017-08-18

Locations

4 sites across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT02200237. Inclusion in this directory is not an endorsement.